πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 111 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12421193

GPR52 modulators and methods of use

Neurocrine Biosciences, Inc. Β· Granted Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12383536

CRF receptor antagonists and methods of use

Neurocrine Biosciences, Inc. Β· Granted Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12128033

Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclo

Neurocrine Biosciences, Inc. Β· Granted Tue Oct 29 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12102637

Pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary

Neurocrine Biosciences, Inc. Β· Granted Tue Oct 01 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12083227

Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic

Neurocrine Biosciences, Inc. Β· Granted Tue Sep 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11730739

Treatment of congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. Β· Granted Tue Aug 22 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 17 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11718618

Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors

Neurocrine Biosciences, Inc. Β· Granted Tue Aug 08 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 03 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11713324

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. Β· Granted Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11654142

Methods for the administration of certain VMAT2 inhibitors

Neurocrine Biosciences, Inc. Β· Granted Tue May 23 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 18 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11459305

Processes for the preparation of uracil derivatives

Neurocrine Biosciences, Inc. Β· Granted Tue Oct 04 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11439629

Methods for the administration of certain VMAT2 inhibitors

Neurocrine Biosciences, Inc. Β· Granted Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11311532

High dosage valbenazine formulation and compositions, methods, and kits related thereto

Neurocrine Biosciences, Inc. Β· Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11311544

Treatment of congenital adrenal hyperplasia

Neurocrine Biosciences, Inc. Β· Granted Tue Apr 26 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11053242

[9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11BH-pyrido-[2,1-a]isoquinolin-2-yl]m

Neurocrine Biosciences, Inc. Β· Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11040029

Methods for the administration of certain VMAT2 inhibitors

Neurocrine Biosciences, Inc. Β· Granted Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11040970

VMAT2 inhibitor compounds and compositions thereof

Neurocrine Biosciences, Inc. Β· Granted Tue Jun 22 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 17 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11033539

Compounds of formulas (VII), (VIII), (IX), (XI), (XII), (XIII), and (XIV) as muscarinic re

Neurocrine Biosciences, Inc. Β· Granted Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 10 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11026931

Methods for the administration of certain VMAT2 inhibitors

Neurocrine Biosciences, Inc. Β· Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11026939

High dosage valbenazine formulation and compositions, methods, and kits related thereto

Neurocrine Biosciences, Inc. Β· Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11021449

Substituted triazoles and methods relating thereto

Neurocrine Biosciences, Inc. Β· Granted Tue Jun 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 27 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10993941

Methods for the administration of certain VMAT2 inhibitors

Neurocrine Biosciences, Inc. Β· Granted Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10952997

Methods for the administration of certain VMAT2 inhibitors

Neurocrine Biosciences, Inc. Β· Granted Tue Mar 23 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10940141

Methods for the administration of certain VMAT2 inhibitors

Neurocrine Biosciences, Inc. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10941159

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

Neurocrine Biosciences, Inc. Β· Granted Tue Mar 09 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 04 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted